Q2 Earnings Estimate for LEXX Issued By Zacks Small Cap

Lexaria Bioscience Corp. (NASDAQ:LEXX) – Stock analysts at Zacks Small Cap issued their Q2 2025 earnings estimates for Lexaria Bioscience in a research report issued on Tuesday, January 28th. Zacks Small Cap analyst J. Vandermosten forecasts that the company will post earnings per share of ($0.14) for the quarter. The consensus estimate for Lexaria Bioscience’s current full-year earnings is ($0.42) per share. Zacks Small Cap also issued estimates for Lexaria Bioscience’s Q3 2025 earnings at ($0.14) EPS, FY2025 earnings at ($0.57) EPS and FY2026 earnings at ($0.45) EPS.

Lexaria Bioscience (NASDAQ:LEXX) last announced its earnings results on Friday, January 10th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.04). Lexaria Bioscience had a negative return on equity of 88.88% and a negative net margin of 1,473.04%.

Separately, HC Wainwright reduced their target price on shares of Lexaria Bioscience from $10.00 to $7.00 and set a “buy” rating on the stock in a research report on Friday, January 24th.

Lexaria Bioscience Stock Up 0.6 %

Shares of LEXX stock opened at $1.82 on Thursday. The stock has a market cap of $31.94 million, a price-to-earnings ratio of -3.64 and a beta of 0.98. The business’s fifty day moving average is $2.14 and its 200 day moving average is $2.70. Lexaria Bioscience has a twelve month low of $1.43 and a twelve month high of $6.85.

Insider Buying and Selling at Lexaria Bioscience

In other Lexaria Bioscience news, CEO Richard Christopher bought 22,828 shares of the firm’s stock in a transaction on Monday, December 2nd. The stock was acquired at an average price of $2.24 per share, with a total value of $51,134.72. Following the transaction, the chief executive officer now owns 22,828 shares in the company, valued at $51,134.72. This represents a ? increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 26.40% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC grew its position in Lexaria Bioscience by 31.0% in the 3rd quarter. Geode Capital Management LLC now owns 150,391 shares of the company’s stock worth $459,000 after purchasing an additional 35,608 shares during the period. Renaissance Technologies LLC bought a new position in shares of Lexaria Bioscience during the 2nd quarter valued at $63,000. XTX Topco Ltd boosted its stake in shares of Lexaria Bioscience by 47.8% in the 3rd quarter. XTX Topco Ltd now owns 18,626 shares of the company’s stock worth $57,000 after buying an additional 6,024 shares during the last quarter. HighTower Advisors LLC bought a new stake in shares of Lexaria Bioscience in the third quarter worth $40,000. Finally, Byrne Asset Management LLC increased its position in Lexaria Bioscience by 132.1% during the fourth quarter. Byrne Asset Management LLC now owns 13,000 shares of the company’s stock valued at $27,000 after acquiring an additional 7,400 shares during the last quarter. 13.06% of the stock is owned by hedge funds and other institutional investors.

Lexaria Bioscience Company Profile

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods.